1. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection.
- Author
-
Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, and Chuang DM
- Subjects
- Animals, Apoptosis drug effects, Apoptosis physiology, Cells, Cultured, Cerebellum cytology, Enzyme Activation drug effects, Enzyme Inhibitors pharmacology, Excitatory Amino Acid Antagonists pharmacology, Glutamic Acid toxicity, JNK Mitogen-Activated Protein Kinases, Lithium pharmacology, MAP Kinase Signaling System drug effects, MAP Kinase Signaling System physiology, Neurons cytology, Neuroprotective Agents pharmacology, Phosphorylation drug effects, Protein Binding physiology, Rats, Rats, Sprague-Dawley, Receptors, N-Methyl-D-Aspartate metabolism, Time, Tumor Suppressor Protein p53 metabolism, p38 Mitogen-Activated Protein Kinases, DNA metabolism, Mitogen-Activated Protein Kinases metabolism, Neurons metabolism, Transcription Factor AP-1 metabolism
- Abstract
In rat cerebellar granule cells, glutamate induced rapid activation of c-Jun N-terminal kinase (JNK) and p38 kinase to phosphorylate c-Jun (at Ser63) and p53 (at Ser15), respectively, and a subsequent marked increase in activator protein-1 (AP-1) binding that preceded apoptotic death. These glutamate-induced effects and apoptosis could largely be prevented by long-term (7 days) pretreatment with 0.5-2 mm lithium, an antibipolar drug. Glutamate's actions could also be prevented by known blockers of this pathway, MK-801 (an NMDA receptor blocker), SB 203580 (a p38 kinase inhibitor) and curcumin (an AP-1 binding inhibitor). The concentration- and time-dependent suppression of glutamate's effects by lithium and curcumin correlated well with their neuroprotective effects. These results suggest a prominent role of JNK and p38, as well as their downstream AP-1 binding activation and p53 phosphorylation in mediating glutamate excitotoxicity. Moreover, the neuroprotective effects of lithium are mediated, at least in part, by suppressing NMDA receptor-mediated activation of the mitogen-activated protein kinase pathway.
- Published
- 2003
- Full Text
- View/download PDF